Filtered By:
Condition: Heart Disease
Management: Hospitals
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 354 results found since Jan 2013.
Late effects of childhood cancer recorded at a single outpatient clinic over the course of one year: implications for the follow-up care
Neoplasma. 2022 Jul 13:220531N584. doi: 10.4149/neo_2022_220531N584. Online ahead of print.ABSTRACTSystematic registration and analysis of detailed treatment data and data on late effects in survivors of childhood cancer are important both for building the evidence base for future assessment of current innovative therapies in pediatric oncology and for personalization of preventive care for survivors of childhood cancer. The paper provides a descriptive analysis of medical data (diagnosis, treatment, late effects, and health status) and selected patient-reported outcomes (mental health and psychosocial well-being) from a s...
Source: Neoplasma - July 12, 2022 Category: Cancer & Oncology Authors: Tomas Kepak Hana Hrstkova Vitezslav Dusek Marta Holikova Lucie Strublova Katerina Kepakova Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial
This study is registered with ClinicalTrials.gov, NCT00924937.FINDINGS: From Oct 1, 2009, to Feb 28, 2012, a total of 1002 patients were enrolled, 500 (49·9%) in the low-fat diet group and 502 (50·1%) in the Mediterranean diet group. The mean age was 59·5 years (SD 8·7) and 827 (82·5%) of 1002 patients were men. The primary endpoint occurred in 198 participants: 87 in the Mediterranean diet group and 111 in the low-fat group (crude rate per 1000 person-years: 28·1 [95% CI 27·9-28·3] in the Mediterranean diet group vs 37·7 [37·5-37·9] in the low-fat group, log-rank p=0·039). Multivariable-adjusted hazard ratios ...
Source: Atherosclerosis - May 7, 2022 Category: Cardiology Authors: Javier Delgado-Lista Juan F Alcala-Diaz Jose D Torres-Pe ña Gracia M Quintana-Navarro Francisco Fuentes Antonio Garcia-Rios Ana M Ortiz-Morales Ana I Gonzalez-Requero Ana I Perez-Caballero Elena M Yubero-Serrano Oriol A Rangel-Zu ñiga Antonio Camargo Fe Source Type: research
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Work stress and loss of years lived without chronic disease: an 18-year follow-up of 1.5 million employees in Denmark
AbstractWe aimed to examine the association between exposure to work stress and chronic disease incidence and loss of chronic disease-free life years in the Danish workforce. The study population included 1,592,491 employees, aged 30 –59 in 2000 and without prevalent chronic diseases. We assessed work stress as the combination of job strain and effort-reward imbalance using job exposure matrices. We used Cox regressions to estimate risk of incident hospital-diagnoses or death of chronic diseases (i.e., type 2 diabetes, coronar y heart disease, stroke, cancer, asthma, chronic obstructive pulmonary disease, heart failure, ...
Source: European Journal of Epidemiology - March 21, 2022 Category: Epidemiology Source Type: research
